KRAS and Patent ductus arteriosus: The MYC oncoprotein contributes to this cell lineage heterogeneity in PDA and combined oncogenic KRAS and activated MYC could drive aggressive phenotypic heterogeneity that may allow the emergence of a chemotherapy resistant state enriched for neuroendocrine differentiation in PDA patients.